Labcorp Holdings Inc. Stock

Equities

LH

US5049221055

Healthcare Facilities & Services

Market Closed - Nyse 04:00:02 2024-06-21 pm EDT 5-day change 1st Jan Change
205.2 USD -1.03% Intraday chart for Labcorp Holdings Inc. +2.69% -9.70%
Sales 2024 * 12.82B Sales 2025 * 13.42B Capitalization 17.3B
Net income 2024 * 958M Net income 2025 * 1.1B EV / Sales 2024 * 1.72 x
Net Debt 2024 * 4.73B Net Debt 2025 * 4.23B EV / Sales 2025 * 1.6 x
P/E ratio 2024 *
18.1 x
P/E ratio 2025 *
15.7 x
Employees 61,975
Yield 2024 *
1.44%
Yield 2025 *
1.42%
Free-Float 99.65%
More Fundamentals * Assessed data
Dynamic Chart
Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials CI
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $258 From $256 MT
HSBC Adjusts Price Target on Laboratory Corp of America Holdings to $210 From $225, Keeps Hold Rating MT
Transcript : Labcorp Holdings Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 02:00 PM
Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio CI
JPMorgan Adjusts Price Target on Laboratory Corp of America Holdings to $243 From $261 MT
Some of the biggest splits in Corporate America RE
Declaration of Voting Results by Laboratory Corporation of America Holdings CI
Declaration of Voting Results by Laboratory Corporation of America Holdings CI
Declaration of Voting Results by Laboratory Corporation of America Holding CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing MT
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating MT
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy CI
Tara Health Files an Exempt Solicitation Statement and Recommend Vote for its Proposal CI
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021. CI
More news
1 day-1.03%
1 week+2.69%
Current month+5.31%
1 month+4.14%
3 months-3.76%
6 months-8.38%
Current year-9.70%
More quotes
1 week
201.10
Extreme 201.1
208.31
1 month
191.97
Extreme 191.97
208.31
Current year
191.97
Extreme 191.97
234.09
1 year
191.97
Extreme 191.97
243.30
3 years
191.97
Extreme 191.97
317.17
5 years
98.02
Extreme 98.02
317.17
10 years
95.61
Extreme 95.61
317.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 13-03-31
Director of Finance/CFO 62 14-06-15
Compliance Officer 65 19-01-31
Members of the board TitleAgeSince
Chief Executive Officer 59 13-03-31
Director/Board Member 68 12-12-31
Director/Board Member 66 06-05-16
More insiders
Date Price Change Volume
24-06-21 205.2 -1.03% 1,070,234
24-06-20 207.4 +0.43% 974,385
24-06-18 206.5 +2.45% 898,878
24-06-17 201.6 +0.84% 604,254

Delayed Quote Nyse, June 21, 2024 at 04:00 pm EDT

More quotes
Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
205.2 USD
Average target price
237.6 USD
Spread / Average Target
+15.76%
Consensus